APA (7th ed.) Citation

Verreault, M., Strutt, D., Masin, D., Anantha, M., Waterhouse, D., Yapp, D., & Bally, M. (2012). Irinophore C™, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model. Journal of Controlled Release, 158(1), 34. https://doi.org/10.1016/j.jconrel.2011.09.095

Chicago Style (17th ed.) Citation

Verreault, M., D. Strutt, D. Masin, M. Anantha, D. Waterhouse, D.T Yapp, and M.B Bally. "Irinophore C™, a Lipid-based Nanoparticulate Formulation of Irinotecan, Is More Effective than Free Irinotecan When Used to Treat an Orthotopic Glioblastoma Model." Journal of Controlled Release 158, no. 1 (2012): 34. https://doi.org/10.1016/j.jconrel.2011.09.095.

MLA (9th ed.) Citation

Verreault, M., et al. "Irinophore C™, a Lipid-based Nanoparticulate Formulation of Irinotecan, Is More Effective than Free Irinotecan When Used to Treat an Orthotopic Glioblastoma Model." Journal of Controlled Release, vol. 158, no. 1, 2012, p. 34, https://doi.org/10.1016/j.jconrel.2011.09.095.